Zydus receives final approval from the USFDA for Acyclovir Ointment

Zydus receives final approval from the USFDA for Acyclovir Ointment ______________________________________________________________ Ahmedabad, 19 March 2019 Zydus Cadila has received the final approval from the USFDA to market Acyclovir Ointment USP (US RLD – Zovirax ®), 5%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non -life- threatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system. The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗